OncoMatch/Clinical Trials/NCT06731933
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Is NCT06731933 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies BVEC for squamous cell carcinoma.
Treatment: BVEC — The study objective is to see if BVEC induced C7 expression in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin following Squamous cell carcinoma (SCC) excision will normalize the invasive tumor microenvironment and reduce tumor recurrence. Prevention of SCC's in the RDEB subjects will increase their life span.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: COL7A1 mutation
Disease stage
Excluded: Stage IV
Prior therapy
Cannot have received: systemic treatment for SCC
is on any current systemic treatment for SCC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Redwood City, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify